Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Notes Payables (2016 - 2019)

Ironwood Pharmaceuticals' Notes Payables history spans 5 years, with the latest figure at $48.8 million for Q2 2019.

  • For Q2 2019, Notes Payables rose 96.28% year-over-year to $48.8 million; the TTM value through Jun 2019 reached $48.8 million, up 96.28%, while the annual FY2018 figure was $47.6 million, N/A changed from the prior year.
  • Notes Payables for Q2 2019 was $48.8 million at Ironwood Pharmaceuticals, up from $46.0 million in the prior quarter.
  • Across five years, Notes Payables topped out at $48.8 million in Q2 2019 and bottomed at $8.4 million in Q3 2016.
  • The 4-year median for Notes Payables is $25.0 million (2015), against an average of $28.2 million.
  • The largest annual shift saw Notes Payables tumbled 58.23% in 2016 before it soared 284.35% in 2019.
  • A 4-year view of Notes Payables shows it stood at $25.0 million in 2015, then plummeted by 66.33% to $8.4 million in 2016, then skyrocketed by 465.78% to $47.6 million in 2018, then increased by 2.61% to $48.8 million in 2019.
  • Per Business Quant, the three most recent readings for IRWD's Notes Payables are $48.8 million (Q2 2019), $46.0 million (Q1 2019), and $47.6 million (Q4 2018).